

ORIGINAL ARTICLE

Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF^{Fbx4/αB-crystallin} ligase and subsequent proteasome-dependent degradation

O Barbash, E Egan, LL Pontano, J Kosak and JA Diehl

Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA

Protein ubiquitylation is a complex enzymatic process that results in the covalent attachment of ubiquitin, through Gly-76 of ubiquitin, to an εNH₂ group of an internal lysine residue in a given substrate. Although E3 ligases frequently use lysines adjacent to the degron within the substrate, many substrates can be targeted to the proteasome through the polyubiquitylation of any lysine. We have assessed the role of lysine residues proximal to the cyclin D1 phosphodegron for ubiquitylation by the SCF^{Fbx4/αB-crystallin} ubiquitin ligase and subsequent proteasome-dependent degradation of cyclin D1. The work described herein reveals a requisite role for Lys-269 (K269) for the rapid polyubiquitin-mediated degradation of cyclin D1. Mutation of Lys-269, which is proximal to the phosphodegron sequence surrounding Thr-286 in cyclin D1, not only stabilizes cyclin D1 but also triggers cyclin D1 accumulation within the nucleus, thereby promoting cell transformation. In addition, D1-K269R is resistant to genotoxic stress-induced degradation, similar to non-phosphorylatable D1-T286A, supporting the critical role for the post-translational regulation of cyclin D1 in response to DNA-damaging agents. Strikingly, although mutation of lysine 269 to arginine inhibits cyclin D1 degradation, it does not inhibit cyclin D1 ubiquitylation *in vivo*, showing that ubiquitylation of a specific lysine can influence substrate targeting to the 26S proteasome. *Oncogene* (2009) 28, 4317–4325; doi:10.1038/onc.2009.287; published online 21 September 2009

Keywords: cyclin D1; Fbx4; ubiquitin; αB crystallin

Introduction

Cell cycle progression is positively regulated by cyclin/cyclin-dependent kinase (cdk) complexes and counteracted through the activity of cdk inhibitors. D-type cyclins are the first cyclins induced as cells enter the cell cycle from G₀, and, together with their catalytic partners cdk4/cdk6, promote G₁/S transition by relieving Rb-dependent repression of E2F transcription

factors (Kato *et al.*, 1993; Matsushime *et al.*, 1994). At the G₁/S boundary, cyclin D1 is phosphorylated at Thr-286 by GSK-3β (glycogen synthase kinase 3β), triggering cyclin D1 nuclear export and subsequent ubiquitin-dependent proteolysis (Diehl *et al.*, 1998). Cytoplasmic ubiquitylation of phosphorylated cyclin D1 is catalyzed by SCF^{Fbx4/αB-crystallin} ligase (Lin *et al.*, 2006).

The importance of maintaining threshold levels of cyclin D1 is emphasized by the frequent cyclin D1 overexpression in human cancer. Cyclin D1 upregulation occurs in 50% of the human breast, esophageal, lung and liver tumors (Sato *et al.*, 1999; Lin and Beerm, 2004). Although ~15% of cases can be attributed to chromosomal translocations and gene amplification (Worsley *et al.*, 1996), inhibition of cyclin D1 proteolysis is either implicated or has been directly shown to be a contributing factor in the majority of such tumors (Moreno-Bueno *et al.*, 2003; Benzeno *et al.*, 2006). In human esophageal cancer, cyclin D1 overexpression occurs through the mutational inactivation of its ubiquitin ligase, Fbx4 (Barbash *et al.*, 2008). In addition, mutations in the cyclin D1 phosphodegron have been observed in human tumors (Moreno-Bueno *et al.*, 2003; Benzeno *et al.*, 2006). Importantly, these findings underline the importance of cyclin D1 proteolysis for normal cell homeostasis, which is often attenuated in human cancer.

Ubiquitin is covalently linked to substrates through the concerted activities of an enzymatic pathway containing the E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 (substrate specificity factor) enzymes through the C-terminal Gly-76 of ubiquitin and the εNH₂ group of the substrate's internal lysine. The molecular basis for the specificity of E3 ligases to particular lysines in substrates is well accepted but is poorly understood (Hershko *et al.*, 1984). Structural studies suggest that the proximity of the substrate lysine chains and E2 enzymes has a pivotal role in the efficiency of substrate ubiquitylation, suggesting that the specificity to the particular lysine can be explained by the relative spatial relationship of these lysines to the E3 ligase (Zheng *et al.*, 2002; Wu *et al.*, 2003). Indeed, some substrates are ubiquitylated only at specific lysines, proximal to the sites of E3 binding, including IκB (Scherer *et al.*, 1995) and p27 (Shirane *et al.*, 1999).

Earlier work had suggested that the mutation of all cyclin D1 lysines to arginine confers protection from proteasome-dependent degradation, whereas the mutations of single lysines only lead to a modest increase in

Correspondence: Professor JA Diehl, Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, 454 BRB II/III, 421 Curie Blvd., Philadelphia, PA 19104, USA.

E-mail: adiehl@mail.med.upenn.edu

Received 4 May 2009; revised 24 July 2009; accepted 12 August 2009; published online 21 September 2009




Figure 1 Mutation of Lys-269 in cyclin D1 leads to increased cyclin D1 protein stability without the attenuation of cyclin D1 functions. (a) NIH-3T3 cells stably expressing wild-type (WT) cyclin D1, D1-K238R and D1-K269R were treated with 100 μ g/ml cycloheximide for the indicated periods of time. Cells were harvested and cyclin D1 protein levels were determined by immunoblotting with the D1-72-13G (D1) antibody. (b) NIH 3T3 cells expressing WT cyclin D1, D1-T286A or D1-K269R were irradiated and harvested, as indicated. Cyclin D1 levels were assessed by immunoblotting. (c) Cell lysates from NIH-3T3 cell lines stably expressing WT cyclin D1, D1-T286A and D1-K269R were used for immunoprecipitation of cyclin D1 with M2 agarose followed by immunoblotting with phospho-Thr-286, D1-72-13G and cdk4 antibodies. (d) Same as (b), immunoblotting with p27 antibody. (e) Cyclin D1/cdk4 complexes were assembled in SF9 cells and used to phosphorylate recombinant glutathione *S*-transferase-Rb, followed by autoradiography.

the stability of cyclin D1 (Feng *et al.*, 2007). This work implicated Lys-112 and Lys-114 as essential ubiquitin acceptors; complicating the interpretation of this work was the fact that these lysine residues also mediate the interaction of cyclin D1 with cdk4 (Feng *et al.*, 2007), and their mutation disrupts the functionality of cyclin D1. In addition, earlier analysis did not address the specificity of lysines as essential acceptors for the E3 ligase, SCF^{Fbx4/zB-crystallin}. We now show that the mutation of Lys-269 (D1-K269R) renders cyclin D1 protein resistant to proteasomal degradation. D1-K269R is resistant to ubiquitylation by SCF^{Fbx4/zB-crystallin} *in vitro*, consistent with increased stability *in vivo*. Critically, cyclin D1-K269R is ubiquitylated *in vivo* and the ubiquitin conjugation of both wild-type (WT) cyclin D1 and D1-K269R *in vivo* occurs through Lys-48-linked polyubiquitin chains. Despite being ubiquitylated *in vivo*, D1-K269R shows diminished association with the 19S proteasomal subunit, suggesting that the ubiquitylation of cyclin D1 at Lys-269 is essential for the targeting of cyclin D1 to proteasome and subsequent degradation.

Results

Mutation of Lys-269 to arginine stabilizes cyclin D1 protein with no attenuation of its functions

Cyclin D1 degradation is triggered by GSK-3 β -dependent phosphorylation and subsequent ubiquitylation by the SCF^{Fbx4/zB-crystallin} complex (Diehl *et al.*, 1998; Lin *et al.*, 2006). To determine whether lysines proximal to Thr-286 of cyclin D1 are essential for the proteasome-dependent degradation of cyclin D1, we generated mutant cyclin D1 alleles in which lysine residues were changed to arginines (D1-K238R and D1-K269R). Although both WT cyclin D1 and D1-K238R showed similar kinetics for proteasomal degradation, the half-life of D1-K269R was extended three- to fourfold (from 20 to 90 min; Figure 1a).

Earlier work showed that cyclin D1 proteolysis induced by γ -irradiation (γ IR) is SCF^{Fbx4/zB-crystallin} dependent (Pontano *et al.*, 2008). Thus, we tested whether D1-K269R is refractory to γ IR-dependent proteasomal degradation. NIH-3T3 cells stably expressing WT cyclin D1, D1-K269R and D1-T286A were exposed to 10 Gy of γ IR (Figure 1b), and the accumulation of cyclin D1,




Figure 2 D1-K269R is resistant to SCF^{Fbx4/αB-crystallin} ubiquitylation *in vitro*. (a) SCF^{Fbx4/αB-crystallin} complexes were assembled in Sf9 cells, purified with M2 agarose and used to ubiquitylate recombinant glutathione *S*-transferase (GST)-D1 or GST-D1-K269R. Reaction mixtures were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by immunoblotting with a cyclin D1 antibody. (b) D1/K4 and D1-K269R/K4 complexes were purified from Sf9 cells using M2 agarose and used for *in vitro* ubiquitylation reaction, as described in (a). (c) SCF^{Fbx4/αB-crystallin} complexes were expressed in Sf9 cells, purified with M2 agarose and mixed with GST-wild-type cyclin D1, D1-T286A or D1-K269R for binding analysis. Complexes were separated by SDS-PAGE, followed by immunoblotting with cyclin D1 and Fbx4 antibodies.

A and E was assessed by immunoblotting at various intervals after γ IR exposure. Although WT cyclin D1 was degraded in response to γ IR, D1-K269R and D1-T286A mutants were stable after γ IR exposure. Thus, the K269R mutation renders cyclin D1 resistant to ubiquitin-dependent proteolysis in proliferating cells after genotoxic stress.

As the phosphorylation of cyclin D1 at Thr-286 is absolutely required for its degradation, we determined whether the K269R mutation might perturb normal phosphorylation of Thr-286 and thereby indirectly affect cyclin D1 degradation. WT and mutant cyclin D1 proteins were immunoprecipitated from asynchronous NIH-3T3 cells that stably express flag-tagged D1 alleles, and phosphorylation was assessed with a phospho-specific Thr-286 antibody. We noted increased Thr-286 phosphorylation of D1-K269R relative to WT cyclin D1. The increase in phosphorylation is expected, given the reduced rate of degradation of cyclin D1-K269R (Figure 1c, panel 1 and 2).

We next determined whether the cyclin D1-K269R mutant retains normal catalytic function and the capacity to bind to p27^{Kip1}. Indeed, co-precipitation revealed that cyclin D1-K269R was associated with p27^{Kip1} (Figure 1d). We subsequently evaluated the ability of cyclin D1-K269R to associate with and induce Cdk4 catalytic activity toward Rb. Immunoprecipitation/western analysis revealed that WT and mutant cyclin D1 both associated with Cdk4 (Figure 1c, lower panel) and efficiently catalyzed Cdk4-dependent phosphorylation of recombinant Rb (Figure 1e). In summary, the mutation of Lys-269 to arginine increases the stability of cyclin D1 without disrupting either the established functional activities of cyclin D1 or the phos-

phorylation signals critical for cyclin D1 degradation. Collectively, these results are consistent with the interpretation that D1-K269R stabilization occurs because of the loss of an essential ubiquitin acceptor residue required for cyclin D1 proteolysis.

Lys-269 of cyclin D1 is essential for SCF^{Fbx4/αB-crystallin}-dependent ubiquitylation 'in vitro'

Given that the Lys-269 to Arg mutation resulted in reduced cyclin D1 degradation, we hypothesized that this mutation would inhibit the ubiquitylation of cyclin D1 by SCF^{Fbx4/αB-crystallin}. We therefore determined the ability of SCF^{Fbx4/αB-crystallin} to directly catalyze the ubiquitylation of WT D1 and D1-K269R *in vitro*. For this experiment, we used glutathione *S*-transferase fusion proteins wherein the C-terminal 41 residues of cyclin D1 (or K269R) are fused in frame with glutathione *S*-transferase. In this fusion, the only available lysine is K269, as lysines within glutathione *S*-transferase are not ubiquitylated. Consistent with the *in vivo* stabilization, purified recombinant SCF^{Fbx4/αB-crystallin} could not catalyze the ubiquitylation of cyclin D1-K269R, although it effectively ubiquitylated WT cyclin D1 *in vitro* (Figure 2a). To ensure that Lys-269 is the ubiquitin acceptor in full-length cyclin D1, we performed the *in vitro* ubiquitylation assay using full-length WT and K269R cyclin D1 purified from Sf9 cells. Again, WT cyclin D1, but not D1-K269R, was effectively ubiquitylated (Figure 2b), suggesting that Lys-269 is an acceptor of ubiquitin from SCF^{Fbx4/αB-crystallin} *in vitro*. Importantly, WT and mutant cyclin D1 retained the ability to bind to SCF^{Fbx4/αB-crystallin} *in vitro*, showing that disruption of ubiquitylation was not because of the inability of D1-K269R to bind to the SCF complex (Figure 2c).

Thus, Lys-269 is required for the efficient cyclin D1 ubiquitylation by the SCF^{Fbx4/αB-crystallin} complex *in vitro*.

Lys-269 of cyclin D1 is not essential for ubiquitylation 'in vivo' but is necessary for rapid proteasome-dependent degradation

As Lys-269 can be ubiquitylated *in vitro*, and is required for proteolytic turnover *in vivo*, we determined whether Lys-269 was necessary for cyclin D1 ubiquitylation *in vivo*. NIH-3T3 cells stably expressing WT cyclin D1 and D1-K269R were treated with the proteasome inhibitor, MG132, and after the lysis of cells under denaturing conditions, ubiquitylated proteins were purified by precipitation using a ubiquitin-specific antibody and cyclin D1 ubiquitylation was assessed by immunoblotting with a flag-reactive antibody (Figure 3a). D1-K269R ubiquitylation was readily apparent *in vivo*, indicating that lysines, besides Lys-269 of cyclin D1, can function as ubiquitin acceptors *in vivo*.

As D1-K269R was ubiquitylated *in vivo*, we determined whether ubiquitin linkages formed on WT cyclin D1 were retained in D1-K269R. Normally, Lys-48-linked polyubiquitin chains provide signals for the targeting of the substrates to the proteasome. As cyclin D1 is degraded in an ubiquitin-dependent manner, we hypothesized that it is ubiquitylated through Lys-48-linked polyubiquitin chains. We transfected NIH-3T3 lines stably expressing WT cyclin D1, D1-T286A and D1-K269R with HA (hemagglutinin)-tagged WT, K48R, K0R and K63R ubiquitin expression vectors. Cells were treated with MG132, and cyclin D1 was immunoprecipitated with the M2 monoclonal antibody; ubiquitylated protein species were visualized by immunoblotting with the HA antibody (Figure 3b). Both WT cyclin D1 and D1-K269R were ubiquitylated *in vivo*, whereas the ubiquitylation of D1-T286A was reduced. The expression of K48R ubiquitin significantly reduced the ubiquitylation of WT cyclin D1, D1-T286A and D1-K269R (Figure 3b), suggesting that the ubiquitin chains formed on cyclin D1 WT and mutants were primarily Lys-48 linked. The expression of K63R ubiquitin only slightly reduced the polyubiquitylation of cyclin D1 alleles, which suggests that the K63-linked ubiquitin chains or mixed K48-linked and K63-linked chains might occasionally form on cyclin D1. In summary, K269R cyclin D1 is a stable mutant of cyclin D1, which is resistant to SCF^{Fbx4/αB-crystallin} ubiquitylation *in vitro*, but is ubiquitylated *in vivo* primarily through the Lys-48 polyubiquitin chains.

On the basis of these data, we suggest that Fbx4 can ubiquitylate additional lysines in cyclin D1, but with reduced processivity. If this is the case, overexpression of Fbx4 should increase the potential cyclin D1–Fbx4 association frequency and potentially increase productive cyclin D1 polyubiquitylation, thereby increasing cyclin D1 degradation. To determine whether D1-K269R degradation is sensitive to Fbx4 levels and thus presumably to steady-state Fbx4 E3 ligase activity, Fbx4 was overexpressed in NIH-3T3 cells stably expressing

D1-K269R (Figure 3c) and cyclin D1-K269R half-life was measured. D1-K269R turnover was modestly accelerated upon Fbx4 overexpression, suggesting that in the absence of Lys-269, SCF^{Fbx4} could modify other lysines, providing alternative signals for cyclin D1 degradation. Consistent with ubiquitylation remaining Fbx4 dependent, expression of the dominant-negative mutant of Fbx4 (ΔF) abolished *in vivo* ubiquitylation of WT and D1-K269R (Figure 3d).

We hypothesized that D1-K269R is ubiquitylated *in vivo*, but the ubiquitylation of Lys-269 is critical for cyclin D1 targeting to the proteasome *in vivo*. To test this notion, NIH-3T3 cells stably expressing WT cyclin D1, D1-K269R and D1-T286A were treated with MG132, followed by immunoprecipitation with M2 agarose and immunoblotting with the antibody to the 19S cap proteasome non-ATPase subunit, PSMD7 (Figure 3d). D1-K269R and D1-T286A showed reduced association with PSMD7 compared with WT cyclin D1, suggesting that D1-K269R targeting the proteasome is attenuated *in vivo*.

D1-K269R shows increased nuclear localization and neoplastic potential

Attenuation of cyclin D1 proteolysis through the inhibition of SCF^{Fbx4/αB-crystallin} function leads to the accumulation of cyclin D1 in the nuclear compartment (Barbash *et al.*, 2008). We therefore anticipated that the mutation of a critical lysine acceptor in cyclin D1 might also result in nuclear accumulation of the mutant cyclin D1 allele. We analyzed the subcellular localization of D1-K269R in NIH-3T3 cells. WT D1 localized to the nucleus in 10% of asynchronous cells and D1-K269R localized to the nucleus in 31% of the cells, whereas the constitutively nuclear D1-T286A mutant had 100% nuclear localization (Figures 4a and b). Therefore, consistent with our earlier observation, the disruption of cyclin D1 proteolysis leads to an increase in the fraction of nuclear cyclin D1. In addition, expression of both WT and K269R cyclin D1 only slightly changed the distribution of cells during the cell cycle (Figure 4c), suggesting that overexpression of both WT cyclin D1 and D1-K269R similarly contribute to cell cycle progression.

Constitutively, nuclear cyclin D1 mutant, D1-T286A, is a potent oncogene in *in vitro* and *in vivo* models. In addition, we have shown earlier that the disruption of cyclin D1 proteolysis through the stable knockdown of either Fbx4 or αB-crystallin in NIH-3T3 cells results in cellular transformation. As D1-K269R is resistant to ubiquitin-dependent proteolysis and has increased nuclear localization, we investigated whether D1-K269R will transform NIH-3T3 cells. Although WT cyclin D1 was weakly transforming, D1-K269R promoted the growth of cells in soft agar (Figures 5a and b) and resulted in foci formation *in vitro* (Figure 5c). In summary, the mutation of Lys-269 renders cyclin D1 resistant to ubiquitin-dependent proteolysis, leading to the accumulation of cyclin D1 in the nuclear compartment and cellular transformation.




Figure 3 *In vivo* ubiquitylation of D1-K269R. (a) NIH-3T3 cells stably expressing wild-type (WT) and K269R cyclin D1 were treated with 10 μ M MG132 for 6 h, and proteins were lysed under denaturing conditions (50 mM Tris-HCl (pH 7.4), 1% sodium dodecyl sulfate (SDS) and 5 mM dithiothreitol). Proteins were precipitated with anti-ubiquitin antibody in the buffer containing 50 mM Tris-HCl (pH 7.4), 250 mM NaCl, 5 mM EDTA and 0.5% NP-40 and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and detected by immunoblotting with a cyclin D1 antibody. (b) NIH-3T3 cells stably expressing WT cyclin D1, D1-T286A and D1-K269R cyclin D1 were transfected with WT, K48R, K0 and K63R ubiquitin constructs. At 48 h post-transfection, cells were treated with 10 μ M MG132 for 6 h and cell lysates were immunoprecipitated with M2 agarose followed by SDS-PAGE of protein complexes and immunoblotting with anti-HA, cyclin D1 and Fbx4 antibodies. (c) NIH-3T3 stably expressing D1-K269R were transfected with an Fbx4 expression vector. At 48 h post-transfection, cells were used for cycloheximide chase assay at the indicated time intervals. Cell lysates were separated by SDS-PAGE, followed by immunoblotting with cyclin D1, Fbx4 and p27 antibodies. (d) 293T cells were transfected with ubiquitin, Δ F-Fbx4 and cyclin D1 constructs, as indicated. At 48 h post-transfection, cells were treated with 10 μ M MG132 for 6 h and cell lysates were immunoprecipitated using the anti-cyclin D1 antibody followed by SDS-PAGE of protein complexes and immunoblotting with the cyclin D1 antibody. (e) Same as in (b), followed by immunoblotting with cyclin D1 and PSMD7 antibodies.

Discussion

Efficient degradation of proteins through the 26S proteasome requires that the proteins are unfolded before access to the catalytic core of the proteasome. Polyubiquitylation of substrates, which generally occurs

on internal lysine residues within the substrate, is postulated to serve as the signal that targets a substrate to the proteasome cap wherein unfoldases and deubiquitinating enzymes unfold the substrate and recycle ubiquitin before its degradation. Previous studies have addressed the role of cyclin D1 lysines in protein




Figure 4 D1-K269R has increased nuclear localization. (a) NIH-3T3 cells stably expressing wild-type (WT) cyclin D1, D1-K269R and D1-T286A were subjected to immunofluorescence analysis with the cyclin D1 antibody (green) and slides were counterstained with DAPI (4',6-diamidino-2-phenylindole) (blue). (b) Quantification of (a) from three independent experiments (error bars represent standard deviation). (c) Cell cycle analysis of asynchronous NIH-3T3 cell lines by propidium iodide/fluorescent-activated cell sorting.




Figure 5 K269R cyclin D1 transforms NIH-3T3 cells. (a) Anchorage-independent growth of NIH-3T3 cells stably expressing wild-type (WT) cyclin D1, D1-T286A, D1-K269R or pBabe-puro vector was analyzed by growth in soft agar. Colonies were visualized by microscopy. (b) Quantification of triplicate samples shown in (a). (c) Foci formation ability of NIH-3T3 cells stably expressing WT cyclin D1, D1-T286A and D1-K269R was determined by Giemsa stain of foci grown for 21 days.

turnover and revealed that the mutations of Lys-112 and Lys-114 extend the cyclin D1 protein half-life; however, these mutations also disrupt a functional interaction

between cyclin D1 and its catalytic partner, cdk4. The degradation of free cyclin D1 is phosphorylation independent (Germain *et al.*, 2000) and thus is not

SCF^{Fbx4/zB-crystallin} dependent (Lin *et al.*, 2006). As cyclin D1 is rarely detected as a monomer (Parry *et al.*, 1999), this mechanism likely contributes to the reduced pool of free cyclin D1. In the current work, we have identified a lysine residue within cyclin D1, near the GSK-3 β phosphorylation site, that targets cyclin D1 for polyubiquitylation by the SCF^{Fbx4/zB-crystallin} ligase. Our findings reveal that Lys-269 of cyclin D1 is essential for cyclin D1 proteolysis. Importantly, the K269R mutation disrupts cyclin D1 ubiquitylation by SCF^{Fbx4/zB-crystallin} complex *in vitro*, implicating Lys-269 as a *bona fide* ubiquitin acceptor site for this E3 ligase.

One surprising observation that has stemmed from this series of experiments is that D1-K269R can still be ubiquitylated *in vivo*. However, although it is ubiquitylated, it remains as resistant to proteasome-dependent degradation as the non-phosphorylatable cyclin D1-T286A allele (Diehl *et al.*, 1997). The potential of cyclin D1 to be ubiquitylated on alternative lysine residues is not unanticipated. In fact, there are instances wherein client proteins are ubiquitylated on the amino-terminal residue in the complete absence of internal lysines (Breitschopf *et al.*, 1998; Bloom *et al.*, 2003). However, the absence of efficient degradation of ubiquitylated D1-K269R shows that it remains a poor substrate for the 26S proteasome. One possible explanation that we considered was alternative ubiquitin linkages, such as K63, which are not associated with degradation. However, ubiquitylation of D1-K269R is dependent on K48 in ubiquitin. A second possibility is that the ubiquitin chains on D1-K269R are of insufficient length and thus poorly recognized by the proteasome. Consistent with this notion, the binding of D1-K269R and PSMD7 (a subunit of the proteasome cap) was reduced relative to that observed with WT cyclin D1.

Our work shows that efficient proteasome-dependent destruction of cyclin D1 requires ubiquitylation of a specific lysine acceptor. Similar mechanisms have been described for cyclin A, in which the mutation of lysines proximal to the D-box (Lys37, 54, 68) extend the half-life of cyclin A that is still ubiquitylated *in vivo* (Fung *et al.*, 2005). In addition, our experiments show that the degradation of D1-K269R is promoted by Fbx4 overexpression, indicating that in the absence of the Lys-269 acceptor site, Fbx4 can promote the degradation of cyclin D1, although with reduced efficacy, through alternative ubiquitylation sites. An alternative possibility is that the stability of cyclin D1 is controlled through the balance of the ubiquitylation and the modifications by other ubiquitin-like proteins, such as SUMO and ISG15 (Feng *et al.*, 2008), in which ubiquitin-like modifiers compete for the acceptor lysines, and thus the K269R mutation might lead to the disruption of ubiquitylation of proximal lysines (such as Lys-238) allowing for their modification with ubiquitin-like proteins and potentially by such means preventing cyclin D1 degradation.

D1-K269R accumulates in cells to higher levels than WT cyclin D1, and D1-K269R localization is shifted to the nuclear compartment. This is consistent with our earlier observation that the inhibition of Fbx4-depen-

dent cyclin D1 ubiquitylation and proteolysis leads to the accumulation of cyclin D1 in the nuclei (Barbash *et al.*, 2008). We show that D1-K269R is phosphorylated at Thr-286, the residue required for nuclear export, suggesting that the increase in the nuclear fraction of D1-K269R is not a result of disrupted phosphorylation-dependent nuclear export. The increase in the nuclear fraction of D1-K269R is likely a result of increased nuclear import of cyclin D1 upon the inhibition of its proteolysis, but the precise mechanism of relocalization requires additional work.

Destruction of nuclear cyclin D1 is required to prevent cyclin D1-dependent cell transformation (Gladden *et al.*, 2006; Aggarwal *et al.*, 2007). Consistent with its increased nuclear accumulation, expression of D1-K269R triggered neoplastic transformation of murine fibroblasts, similar to the overexpression of cyclin D1-T286A or downregulation of Fbx4 (Barbash *et al.*, 2008). One of the mechanisms whereby nuclear cyclin D1 promotes tumorigenesis is through attenuation of Cullin-4 expression with subsequent accumulation of its substrate, replication factor, Cdt1 (Aggarwal *et al.*, 2007). As a consequence, cells expressing constitutively nuclear cyclin D1 show overreplication phenotype and chromosomal abnormalities. Indeed, cells expressing D1-K269R show significant downregulation of Cul4A expression (data not shown), suggesting a common with T286A mechanisms of oncogenic transformation.

In summary, our work shows that Lys-269 is a ubiquitin acceptor site for SCF^{Fbx4/zB-crystallin}. The data presented underline the importance of Lys-269 ubiquitylation for cyclin D1 degradation during cell cycle and in response to genotoxic stress. Our experiments suggest that despite the fact that multiple lysines in cyclin D1 can be ubiquitylated *in vivo*, the ubiquitylation of Lys-269 provides a critical basis for cyclin D1 degradation.

Materials and methods

Cell culture, plasmids and transfections

NIH-3T3 cells were maintained in Dulbecco's modified Eagle's medium containing 10% of fetal bovine serum, glutamine and antibiotics. As indicated, 24h before transfection, cells were plated at optimal density and on the following day transfected using the Lipofectamine Plus reagent (Invitrogen, Carlsbad, CA, USA). Stable cell lines expressing cyclin D1 were generated by puromycin (Sigma-Aldrich, St Louis, MO, USA) selection (5 μ g/ml) for 21 days and subsequently cultured in medium containing 2.5 μ g/ml puromycin. Insect Sf9 cells were maintained as described elsewhere. Flag-tagged cyclin D1 mutants were constructed using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using the pFlex-cyclin D1 plasmid as template. PCR reactions were performed according to the manufacturer's instructions. Clones were sequenced in their entirety to confirm the presence of mutations.

Immunoprecipitation and immunoblot analysis

Cells were lysed in buffer containing: 50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 8.0), 150 mM NaCl, 2.5 mM ethylene glycol tetraacetic acid, 1 mM

EDTA, 0.1% Tween 20, protease and phosphatase inhibitors (1 mM phenylmethanesulfonylfluoride, 20 U/ml aprotinin, 5 µg/ml leupeptin, 1 mM dithiothreitol, 0.4 mM NaF, 10 mM β-glycerophosphate and 100 nM okadaic acid). The protein concentration was determined by BCA assay (Pierce, Rockford, IL, USA). Where indicated, cyclin D1 was precipitated using either M2 agarose (Sigma-Aldrich) or a cyclin D1 mouse monoclonal antibody, D1-72-13G. Proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and analyzed by immunoblotting. Antibodies used were as follows: Fbx4 rabbit polyclonal antibody (Rockland, Gilbertsville, PA, USA), cyclin D1 mouse monoclonal D1-72-13G, β-actin, flag rabbit polyclonal antibody (Sigma-Aldrich), p27 mouse monoclonal antibody, CDK4 (BD Pharmingen, San Diego, CA, USA), ubiquitin mouse monoclonal antibody (Covance, Emerville, CA, USA), cyclin E rabbit polyclonal, and cyclin A rabbit polyclonal antibodies (Santa Cruz, Santa Cruz, CA, USA).

Cycloheximide chase analysis

For cycloheximide chase experiments, NIH-3T3 cells were plated at equal densities and on the next day, asynchronous cells were treated with cycloheximide (100 µg/ml, Sigma-Aldrich) for the indicated periods of time. Cells were lysed in buffer (as described above) and processed for immunoblot analysis.

In vitro kinase assay

Cyclin D1/cdk4 complexes were expressed in Sf9 cells. Cells were lysed in Tween-20 buffer and immunoprecipitated using M2 agarose (Sigma-Aldrich). Purified complexes were mixed with recombinant glutathione *S*-transferase-Rb as described earlier (Matsushime *et al.*, 1994) and the phosphorylation of Rb was determined by autoradiography.

In vitro ubiquitylation

SCF^{Fbx4/zB-crystallin} complexes were purified from Sf9 cells using M2 agarose, mixed with purified substrate, as indicated, that had been phosphorylated *in vitro* with recombinant GSK-3β (5U), E1, E2 (UbcH5A), ATP and ubiquitin for the indicated periods of time at 37°C. Proteins were resolved on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and visualized by western blotting with the D1-72-13G11 antibody.

Immunofluorescence

NIH3T3-derived cell lines were plated at optimal density on glass coverslips. At 24 h after splitting, cells were permeabilized with methanol:acetone (1:1), washed with phosphate-buffered saline and incubated in primary antibody (cyclin D1 17-13G11) for 2 h. After washing and incubation with secondary anti-mouse

fluorescein isothiocyanate-conjugated antibody (GE Healthcare, Piscataway, NJ, USA), slides were mounted using the ProLong Gold anti-fade DAPI (4',6-diamidino-2-phenylindole) reagent (Invitrogen) and analyzed by fluorescent microscopy using the Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan). For quantification of immunofluorescence data, we counted 100 cells for each cell line in three independent experiments.

Transformation assays

Anchorage-independent growth was determined by analyzing cellular growth in semisolid medium. Cells (5×10^3) were seeded in complete Iscove's media containing 0.65% noble agar and 10% fetal calf serum. Cells were grown for 21 days in 8% CO₂. For foci formation, cells were plated at 1.5×10^5 cells per well of a six-well plate. Cells were cultured in medium containing 5% fetal bovine serum. Foci were visualized after 21 days with Wright Giemsa stain (Sigma-Aldrich).

γIR treatment

Asynchronously proliferating NIH-3T3 cells stably expressing WT cyclin D1, D1-T286A or D1-K269R were subjected to 10 Gy γIR, followed by recovery at 37°C. Cell lysates were prepared in Tween-20 buffer, followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting with the following antibodies: cyclin D1, cyclin E, cyclin A and β-actin.

Cell cycle analysis

NIH 3T3 cells stably expressing cyclin D1 or D1-K269R were harvested and washed with phosphate-buffered saline, fixed with ethanol and stained with propidium iodide for 1 h before fluorescent-activated cell sorting analysis. Cell cycle profiles based on DNA content were established by using the FlowJo software.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

We wish to thank Serge Fuchs for the plasmids encoding the various ubiquitin lysine-arginine mutants, and Petia Zamfirova and Margarita Romero for their technical assistance. This work was supported by CA93237 (NIH) and a Leukemia & Lymphoma Scholar award (JAD).

References

- Aggarwal P, Lessie MD, Lin DI, Pontano L, Gladden AB, Nuskey B *et al.* (2007). Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. *Genes Dev* **21**: 2908–2922.
- Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H *et al.* (2008). Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin d1 overexpression in human cancer. *Cancer Cell* **14**: 68–78.
- Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG *et al.* (2006). Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. *Oncogene* **25**: 6291–6303.
- Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. (2003). Proteasome-mediated degradation of p21 via N-terminal ubiquitylation. *Cell* **115**: 71–82.
- Breitschopf K, Bengal E, Ziv T, Admon A, Ciechanover A. (1998). A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. *EMBO J* **17**: 5964–5973.
- Diehl JA, Cheng M, Roussel MF, Sherr CJ. (1998). Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. *Genes Dev* **12**: 3499–3511.
- Diehl JA, Zindy F, Sherr CJ. (1997). Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. *Genes Dev* **11**: 957–972.

- Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F *et al.* (2008). UBE1L causes lung cancer growth suppression by targeting cyclin D1. *Mol Cancer Ther* **7**: 3780–3788.
- Feng Q, Sekula D, Muller R, Freemantle SJ, Dmitrovsky E. (2007). Uncovering residues that regulate cyclin D1 proteasomal degradation. *Oncogene* **26**: 5098–5106.
- Fung TK, Yam CH, Poon RY. (2005). The N-terminal regulatory domain of cyclin A contains redundant ubiquitination targeting sequences and acceptor sites. *Cell Cycle* **4**: 1411–1420.
- Germain D, Russell A, Thompson A, Hendley J. (2000). Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. *J Biol Chem* **275**: 12074–12079.
- Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. (2006). Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. *Oncogene* **25**: 998–1007.
- Hershko A, Heller H, Eytan E, Kaklij G, Rose IA. (1984). Role of the alpha-amino group of protein in ubiquitin-mediated protein breakdown. *Proc Natl Acad Sci USA* **81**: 7021–7025.
- Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. (1993). Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. *Genes Dev* **7**: 331–342.
- Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ *et al.* (2006). Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF (FBX4-alphaB crystallin) complex. *Mol Cell* **24**: 355–366.
- Lin J, Beerm DG. (2004). Molecular biology of upper gastrointestinal malignancies. *Semin Oncol* **31**: 476–486.
- Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. (1994). D-type cyclin-dependent kinase activity in mammalian cells. *Mol Cell Biol* **14**: 2066–2076.
- Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Hardisson D, Sarrio D, Prat J *et al.* (2003). Cyclin D1 gene (CCND1) mutations in endometrial cancer. *Oncogene* **22**: 6115–6118.
- Parry D, Mahony D, Wills K, Lees E. (1999). Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. *Mol Cell Biol* **19**: 1775–1783.
- Pontano LL, Aggarwal P, Barbash O, Brown EJ, Bassing CH, Diehl JA. (2008). Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. *Mol Cell Biol* **28**: 7245–7258.
- Sato Y, Itoh F, Hareyama M, Satoh M, Hinoda Y, Seto M *et al.* (1999). Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. *J Gastroenterol* **34**: 486–493.
- Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW. (1995). Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. *Proc Natl Acad Sci USA* **92**: 11259–11263.
- Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S *et al.* (1999). Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. *J Biol Chem* **274**: 13886–13893.
- Worsley SD, Jennings BA, Khalil KH, Mole M, Girling AC. (1996). Cyclin D1 amplification and expression in human breast carcinoma: correlation with histological prognostic markers and oestrogen receptor expression. *Clin Mol Pathol* **49**: M46–M50.
- Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. (2003). Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. *Mol Cell* **11**: 1445–1456.
- Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P *et al.* (2002). Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. *Nature* **416**: 703–709.